110 related articles for article (PubMed ID: 38830680)
1. Strategies to accelerate the elimination of cervical cancer in British Columbia, Canada: a modelling study.
Pataky RE; Izadi-Najafabadi S; Smith LW; Gottschlich A; Ionescu D; Proctor L; Ogilvie GS; Peacock S
CMAJ; 2024 Jun; 196(21):E716-E723. PubMed ID: 38830680
[TBL] [Abstract][Full Text] [Related]
2. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
3. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
4. The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.
Keane A; Ng CW; Simms KT; Nguyen D; Woo YL; Saville M; Canfell K
Int J Cancer; 2021 Dec; 149(12):1997-2009. PubMed ID: 34363620
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
[TBL] [Abstract][Full Text] [Related]
7. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
8. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
9. Modelling cervical cancer elimination using single-visit screening and treatment strategies in the context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa.
Rao DW; Bayer CJ; Liu G; Chikandiwa A; Sharma M; Hathaway CL; Tan N; Mugo N; Barnabas RV
J Int AIDS Soc; 2022 Oct; 25(10):e26021. PubMed ID: 36225139
[TBL] [Abstract][Full Text] [Related]
10. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
11. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study.
Xia C; Hu S; Xu X; Zhao X; Qiao Y; Broutet N; Canfell K; Hutubessy R; Zhao F
Lancet Public Health; 2019 Sep; 4(9):e462-e472. PubMed ID: 31493843
[TBL] [Abstract][Full Text] [Related]
12. Projected time to elimination of cervical cancer in the USA: a comparative modelling study.
Burger EA; Smith MA; Killen J; Sy S; Simms KT; Canfell K; Kim JJ
Lancet Public Health; 2020 Apr; 5(4):e213-e222. PubMed ID: 32057315
[TBL] [Abstract][Full Text] [Related]
13. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
14. Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program.
Racey CS; Albert A; Donken R; Smith L; Spinelli JJ; Pedersen H; de Bruin P; Masaro C; Mitchell-Foster S; Sadarangani M; Dawar M; Krajden M; Naus M; van Niekerk D; Ogilvie G
J Infect Dis; 2020 Jan; 221(1):81-90. PubMed ID: 31504649
[TBL] [Abstract][Full Text] [Related]
15. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
16. High-risk HPV prevalence among women undergoing cervical cancer screening: Findings a decade after HPV vaccine implementation in British Columbia, Canada.
Litwin C; Smith L; Donken R; Krajden M; van Niekerk D; Naus M; Cook D; Albert A; Ogilvie G
Vaccine; 2021 Aug; 39(36):5198-5204. PubMed ID: 34344555
[TBL] [Abstract][Full Text] [Related]
17. Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study.
Jansen EEL; de Kok IMCM; Kaljouw S; Demirel E; de Koning HJ; Hontelez JAC
BMC Med; 2022 Nov; 20(1):433. PubMed ID: 36352410
[TBL] [Abstract][Full Text] [Related]
18. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
19. Impact of human papillomavirus age-related prevalence and vaccination levels on interpretation of cervical screening modalities: a modelling study.
Grimes DR
BMJ Open; 2024 Feb; 14(2):e078551. PubMed ID: 38309749
[TBL] [Abstract][Full Text] [Related]
20. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
Hall MT; Simms KT; Lew JB; Smith MA; Saville M; Canfell K
PLoS One; 2018; 13(2):e0185332. PubMed ID: 29444073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
